Zhou Ting, Liu Mengting, Pan Jialiang, Ren Jianluan, Tang Fang, Dai Jianjun, Xue Feng, Ji Dejun
International Joint Research Laboratory of Animal Health and Food Safety, Key Laboratory of Animal Bacteriology, Ministry of Agriculture, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.
Department of Aquaculture, Animal Science DEPT, Yangzhou University, Yangzhou 225100, China.
Life (Basel). 2022 Oct 29;12(11):1740. doi: 10.3390/life12111740.
With the discovery of more and more drug-resistant bacterial strains, there is an urgent need for safer and more effective alternative treatments. In this study, antibacterial peptides and probiotic microcapsules were combined to treat gastrointestinal inflammation caused by infection.
To improve the stability of probiotics in the gastrointestinal tract, two types of mixed natural anionic polysaccharides and chitosan were used as carriers to embed the probiotics. Taking CGMCC1.8727 microcapsules with good performance as the research object, the in vitro characteristics of the microcapsules were studied via acid resistance test and intestinal release test. The microcapsules were then tested for in vivo treatment in combination with the antibacterial peptide, bomidin, and the therapeutic effects were compared among microencapsulated probiotics, free probiotics, and probiotics in combination with bomidin.
Microencapsulation was successfully manufactured under suitable processing parameters, with the product particle size being 2.04 ± 0.2743 mm. Compared with free probiotics, microencapsulation significantly improved the activity and preservation stability of the probiotics under simulated gastrointestinal conditions. Microencapsulated probiotics showed better therapeutic effects than free probiotics in vivo. Microcapsules combined with antimicrobial peptides accelerated the elimination of bacteria in vivo. This study provides a reference for anti-inflammatory treatment, especially for the treatment of gastrointestinal diseases.
随着越来越多耐药细菌菌株的发现，迫切需要更安全、更有效的替代治疗方法。在本研究中，将抗菌肽与益生菌微胶囊联合用于治疗由感染引起的胃肠道炎症。
为提高益生菌在胃肠道中的稳定性，使用两种混合的天然阴离子多糖和壳聚糖作为载体来包埋益生菌。以性能良好的CGMCC1.8727微胶囊为研究对象，通过耐酸性试验和肠道释放试验研究微胶囊的体外特性。然后将微胶囊与抗菌肽波米丁联合进行体内治疗测试，并比较微囊化益生菌、游离益生菌以及益生菌与波米丁联合使用的治疗效果。
在合适的加工参数下成功制备了微胶囊，产品粒径为2.04±0.2743毫米。与游离益生菌相比，微囊化显著提高了益生菌在模拟胃肠道条件下的活性和保存稳定性。微囊化益生菌在体内显示出比游离益生菌更好的治疗效果。微胶囊与抗菌肽联合使用可加速体内细菌的清除。本研究为抗炎治疗，特别是胃肠道疾病的治疗提供了参考。
